Found: 6
Select item for more details and to access through your institution.
Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
- Published in:
- Science Signaling, 2018, v. 11, n. 551, p. 1, doi. 10.1126/scisignal.aat9773
- By:
- Publication type:
- Article
Mammalian Raf-1 is activated by mutations that restore Raf signaling in Drosophila.
- Published in:
- EMBO Journal, 1997, v. 16, n. 8, p. 1953, doi. 10.1093/emboj/16.8.1953
- By:
- Publication type:
- Article
Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations.
- Published in:
- Breast Cancer Research & Treatment, 2019, v. 174, n. 1, p. 55, doi. 10.1007/s10549-018-5049-7
- By:
- Publication type:
- Article
Physiologically‐based pharmacokinetic modelling to predict oprozomib CYP3A drug–drug interaction potential in patients with advanced malignancies.
- Published in:
- British Journal of Clinical Pharmacology, 2019, v. 85, n. 3, p. 530, doi. 10.1111/bcp.13817
- By:
- Publication type:
- Article
Neratinib augments the lethality of [regorafenib + sildenafil].
- Published in:
- Journal of Cellular Physiology, 2019, v. 234, n. 4, p. 4874, doi. 10.1002/jcp.27276
- By:
- Publication type:
- Article